Picture this: Your Phase 2 trial is in the books. The data looks promising, and you’re standing at a critical inflection point. The question is no longer whether the science works; it’s how to move from a handful of patients to a broader market.

Scaling up isn’t just about adding people or infrastructure. It’s about transforming from an R&D-focused team into a commercial engine that can operate at market speed. And with that shift comes new pressures: tighter regulatory scrutiny, mounting competitive threats, and the complexity of managing external partners without losing control.

Here, we’ll break down the three pillars that determine whether scale-up strengthens your position or stalls momentum: navigating regulatory change, outmaneuvering competitors, and making smart use of CRO partnerships. We’ll also show how the right growth strategy consultant can help pharma companies connect these pieces into a foundation for sustainable success, so you can stay focused on advancing the science and serving patients.

Regulatory: Scaling Without Losing Compliance

Moving from R&D to commercial operations puts a spotlight on compliance. What worked for a small trial site may not withstand the scrutiny of Good Manufacturing Practices (GMP) or evolving clinical trial standards. At this stage, compliance isn’t just a hurdle; it’s the backbone of sustainable growth. The companies that scale successfully are those that embed regulatory readiness into their operational DNA from day one.

ICH E6(R3): A Shift in Clinical Practice Standards

The International Council for Harmonisation (ICH) rolled out its updated Good Clinical Practice guidelines, ICH E6(R3), which took effect in the EU in January 2025. This isn’t just a minor edit; it moves the industry away from a prescriptive, one-size-fits-all model toward a flexible, risk-based approach. The new guidelines encourage the use of modern technologies and a “quality by design” mindset, focusing on identifying and mitigating risks to patient safety and data integrity from the beginning of a trial.

Strategic Takeaway

Small and mid-sized pharma firms can use these changes to their advantage by adopting digital-first tools and risk-mitigation planning earlier than larger competitors who may be slower to adapt. A regulatory compliance consultant can help pressure-test where compliance overlaps with efficiency.

From the Source: Guideline for Good Clinical Practice E6(R3)

Trials With Decentralized Elements

In September 2024, the FDA finalized its guidance on “Conducting Clinical Trials With Decentralized Elements.” The message was clear: The same regulatory requirements apply whether activities occur at a central site or are distributed across telehealth visits, local healthcare providers, home delivery of investigational products, or digital health technologies. These elements can make trials more accessible and improve recruitment, but they also raise the stakes for oversight.

For sponsors, the challenge is twofold: ensuring participant safety in remote interactions and maintaining the accuracy and reproducibility of data collected outside traditional sites. Investigators remain fully accountable, including for the qualifications of local HCPs, and all processes must still produce records that stand up to FDA inspection.

Strategic Takeaway

For scaling pharma companies, decentralized elements are less about “doing trials efficiently” and more about integrating new flexibilities without losing regulatory footing. A strategic growth advisory consultant can help design frameworks that balance innovation and compliance: benchmarking governance structures, mapping risks, and embedding monitoring tools that satisfy FDA expectations while maintaining operational speed.

From the Source: FDA Final Guidance: Conducting Clinical Trials With Decentralized Elements

Timelines Drive Operational Planning

In commercial-scale pharma, product launches aren’t one-off milestones; they’re repeatable, high-stakes processes that demand precision. Regulatory timelines leave little room for error: Missing a filing window or underestimating review cycles can delay approval and erode market opportunity. To stay ahead, companies often need to begin operational planning 18–24 months before launch, aligning cross-functional teams on a single roadmap and engaging regulators early to reduce uncertainty.

Strategic Takeaway

A strategic growth consultant can pressure-test these plans by mapping dependencies, modeling potential bottlenecks, and building adaptive launch frameworks that hold up under regulatory scrutiny. This foresight helps smaller pharma firms avoid costly missteps and position themselves to hit launch dates with confidence.

From the Source: FDA Guidance: Formal Meetings Between the FDA and Sponsors/Applicants

Data Readiness As a Regulatory Focus

Every submission now hinges on data integrity, and scaling multiplies both the volume and complexity of data flowing from manufacturing, supply chain, and clinical trials. Regulators are no longer satisfied with checking the end product; they increasingly scrutinize the systems, controls, and audit trails used to manage data. Inconsistent records or weak governance can slow approval or even derail a launch.

Strategic Takeaway

Embedding strong data governance and digital monitoring tools doesn’t just reduce compliance risk; it can actively accelerate approval by demonstrating reliability and transparency. Growth strategy consultants can benchmark your data readiness against competitors, highlight where digital systems can replace manual gaps, and help you build a data architecture that reassures regulators and investors alike. In today’s market, a pharma company that can prove its data is trustworthy gains both regulatory confidence and a competitive edge.

From the Source: FDA Guidance: Data Integrity and Compliance With Drug CGMP

The Competitive Space for Pharma

Scaling up in pharma is about more than hitting regulatory milestones. It relies on the ability to outmaneuver competitors in a market defined by scarcity, risk, and rapid change. Growth depends on a clear-eyed view of two forces that shape the playing field: clinical success rates and the looming patent cliff.

Probability of Success by Phase

The pharmaceutical industry is a high-risk, high-reward business, with the odds stacked against every new molecule. The reality is stark: most molecules don’t make it. 

On average, only about 10% of drugs that enter Phase 1 clinical trials ever achieve FDA approval. The riskiest point is often Phase 2, where efficacy questions can halt a project. Even a successful Phase 3 trial doesn’t guarantee victory. For scaling companies, this underscores the importance of a diversified pipeline and scenario planning, not betting everything on a single trial outcome.

Patent Cliffs and Portfolio Pressure

Intellectual property defines the revenue window. Patents provide temporary exclusivity, but when they expire, generics and biosimilars rapidly erode market share. 

The 2025–2030 horizon represents one of the sharpest patent cliffs in recent history, with blockbusters from Bristol Myers Squibb and Merck set to lose exclusivity. For smaller companies, this creates both a threat and an opportunity: established giants are forced to replenish portfolios, often through partnerships, acquisitions, or licensing deals.

Strategic Takeaway

In this environment, competitive strategy consulting helps pharma companies pressure-test their portfolios, identify white-space opportunities, and plan for both internal growth and external partnerships. Consultants can map competitor pipelines, model market-entry scenarios, and build strategies to seize advantage in the churn of expiring patents and high trial attrition.

From the source: Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’ (BioPharma Dive)

Where CROs Fit When Pharma Companies Scale

As a pharma company grows, it often has to ask: How much of our core R&D and clinical work should we keep in-house, and how much should we trust to a partner? This decision can make or break timelines, budgets, and, ultimately, market success.

More than just a cost-saving option, the modern Contract Research Organization (CRO) provides access to specialized expertise, advanced technology, and scale that’s difficult or impractical to build internally. The global pharmaceutical CRO market is projected to reach nearly $63 billion by 2030, underscoring how central these partnerships have become for scaling companies.

How Much Outsourcing Is Standard?

There’s no one-size-fits-all answer here. Smaller companies may rely on CROs for nearly 100% of clinical development, while larger firms often outsource roughly half of their activities. The right balance depends on internal capabilities, project goals, and the level of control required. A strong CRO provides flexibility, allowing a company to scale functions without hiring and training large internal teams.

What You Can Delegate (and What You Can’t)

You can delegate a lot, but you can’t delegate accountability. The sponsor (you) always retains ultimate responsibility for the quality and integrity of the trial data and the final product.

With that said, common tasks you can hand off to a CRO can include:

• Clinical trial management: Site selection, patient recruitment, and monitoring

• Data management and biostatistics: Handling the mountain of data from a large trial, from collection to analysis

• Regulatory affairs: Assisting with documentation preparation and submission to agencies like the FDA

• Pharmacovigilance: Monitoring and reporting adverse events

So, what should you keep in-house? Core functions that define your company’s identity and path forward:

• Strategic oversight: The big-picture decisions about your pipeline and development plans

• Intellectual property management: The safeguarding of your proprietary know-how and patents

• Core scientific innovation: The initial discovery and design of your drug

How CROs Engage

CRO engagement models have evolved beyond transactional, fee-for-service arrangements. Most modern partnerships are more collaborative and strategic.

The two most common models are:

• Full-service outsourcing (FSO): A company hires a single CRO to handle all or most of a project from start to finish. This is great for smaller companies that need a plug-and-play solution and lack the internal resources to manage multiple vendors.

• Functional service provider (FSP): A specific function, like data management or clinical monitoring, is outsourced to a dedicated team at a CRO. This offers more flexibility and is often favored by larger pharma companies that have strong internal project management but need to scale a specific function quickly.

CRO Selection Factors That Matter in Pharma

Selecting the right CRO is as much about partnership chemistry as capabilities.

When selecting a CRO, consider:

• Therapeutic expertise: Does the CRO have a proven track record in your specific therapeutic area (e.g., oncology, rare disease)?

• Technology and data infrastructure: Do their systems integrate seamlessly with yours? Can they handle complex data sets and ensure security?

• Regulatory and quality track record: Do they have a good reputation with regulatory bodies and a strong quality-assurance program?

• Cultural fit: This one is often overlooked, but it can make or break the engagement. Do their teams communicate effectively? Are they truly collaborative partners, or just order-takers?

Partnering for Profitability and Resilience

Scaling a pharmaceutical business is complex, but it doesn’t have to be overwhelming. The right strategic growth advisory expert can help you streamline operations, navigate regulatory hurdles, and make informed decisions about partnerships and outsourcing. By bringing in external support, you can free internal teams to focus on what they do best: advancing science, delivering patient value, and driving pipeline success.

At FP360, we don’t just offer advice; we embed ourselves as operational partners, helping you benchmark performance, optimize processes, and anticipate competitive pressures before they become risks. Our competitive analysis and growth strategy consulting services provide a clear line of sight across the regulatory landscape, market dynamics, and internal operations, so you can scale confidently and sustainably.

Ready to take the next step? Schedule a consultation today to explore how our strategic growth consulting team can help your company turn complex scale-up challenges into a repeatable, high-performing commercial engine.